Lilly guides to $80-83 billion 2026 sales as Novo forecasts decline
Novo expects sales and profit to fall 5% to 13% this year as US prices drop and semaglutide exclusivity lapses in China, Brazil and Canada.
The wire
- 01Lilly forecast 2026 revenue of $80 billion to $83 billion, above the $77.62 billion consensus and implying 25% growth, while Novo Nordisk guided to a 5% to 13% decline in sales and profit.
- 02Both companies flagged a low- to mid-teens percentage global price decline following November most-favored-nation deals with the Trump administration, a shift pharmacists and telehealth operators will see in cash-pay pricing.
- 03Lilly is counting on Medicare obesity coverage starting by at least July and a second-quarter oral GLP-1 launch; CEO David Ricks said 20 million to 25 million patients currently take the two companies' medicines.
From the source
Read at cnbc.comEli Lilly's GLP-1 growth is only getting started as Novo Nordisk braces for a decline in 2026
It's a tale of two drugmakers in the red-hot obesity drug market.